Summary
There is a significant increase in Aseptic processing as more and more products and advance therapies are developed with biological mechanisms that are impacted by Terminal Sterilisation. The revision and implementation of EU GMP & PICS Annex 1 has significantly impacted Aseptic processing; in design, control, qualification, monitoring and product testing. It is important to understand these challenges and regulatory requirements/ trends and join the discussion on how we meet these challenges.
This 3-day online training will cover GMP regulations and regulatory expectations in Aseptic manufacturing of sterile medicinal products and ATMPs including key points in compliance to the revised EU GMP Annex 1 that encourages increased application of Quality Risk Management (QRM) principles (ICHQ9(R1)) over the product life cycle (ICHQ12). Details will be provided of manufacturing technologies to improve efficiencies and GMP compliance together with guidance on how to prepare a Contamination Control Strategy (CCS) and if required aseptic-containment strategy. The training extends into process operations covering best practices; Good aseptic technique, good Cleanroom behaviour together with good training practices (including increased use of VR (virtual reality).
The connection between Control Strategies though CMC and GMP, including Cross contamination Control strategies will be discussed for ATMPs and Biologics. Small and large molecule processing will be considered in downstream processing where bioburden control applies and connection to Aseptic process with Fill and Finish in different dose forms: Vials, Syringes, Ampoules, Cartridges and IV Bags
Background
The revision of Annex 1 EU GMP for manufacture of sterile medicinal products marks a paradigm shift in regulations taking a more risk based, holistic and proactive approach to managing contamination and product quality in manufacturing. To support the paradigm shift ICHQ9(R1) QRM: Quality risk management has been revised to focus on hazard and risk knowledge before applying risk control mitigations to move away from the subjectivity of risk assessments that tend to focus on risk priority numbers (RPNs) that can lead to poor justifications of unacceptable risks. Regulators consider the full benefit of QRM is not being realised hence the revision of ICHQ9 (R1) and direct linkage to Annex 1 to engage this essential principle. Such regulatory changes impact key elements of aseptic processing and keeping current requires an understanding of these changes and impact. This essential training will cover key points to consider as result of regulatory changes and possible solutions to regulatory requirements that may be an expected or necessary process improvement.
Who should attend?
This course will cover a range of aspects in aseptic processing that will be of interest to: QA/QPs and QC, Facility and process design, Materials Science and Technologies (MSAT), Manufacturing operations, Aseptic processing technology specialists, GMP consultants and auditors
Key takeaways
Changes in regulations and new GMP requirements challenge all industries but also considering the growth in biologics/ ATMPs for more targeted personalised/ individualised medicines and the paradigm shift away from big ‘block buster products’ the need to understand aseptic processing and regulatory expectations has never been more current. Vaccines have become a new ‘Block buster’ manufactured at large batch scale that use biologics requiring aseptic processing with high efficiencies provided by automation.
New aseptic processing platforms are following five ‘pillars’ that characterise an advanced approach, including: Flexibility, Modularity, Intensification, Digitalisation and Automation.
Key takeaways include
- GMP regulation changes and their impact on Aseptic processing
- QRM what this really means and how it is applied
- Contamination Control Strategy (CCS) and considerations in aseptic processing
- Barrier separation technologies, alternatives for aseptic processing of different product types e.g., Pharmaceuticals, biologicals, ATMPs and toxic products – small and large batches
- Application of single use systems, RTU: Ready to Use product containers and closures in barrier technologies considering transfers into Grade A and bio-compatibilities
- Application of large batch vial filling for liquid and freeze-dried products considering environmental zoning in transfers, application of UDAF, localised UDAF and Grade A air supply plus the surrounding environment
- Integration of automation with GMP compliance in manufacturing environments
- How to apply EM and PM as measures of collective effectiveness of contamination control measures
- Digitalisation of data, data analysis/ trending and data to support batch release.
- Future trends in aseptic processing
Our online training experience includes
- Our client zone – a single source for all training materials as well as pre and post-training communication
- Live interactive format via the Zoom platform
- Direct interaction with the trainer
- Q&As, case studies, polls
- Revisit recorded sessions for 7 days
- Training in digital format
- Digital and LinkedIn certificates
Trainers
Aseptic Processing in Manufacture of Sterile Products & ATMPs
Download the full training agenda to reveal complete session details, training takeaways, case studies, daily schedule, special features and full trainer bio.
